Alaunos Therapeutics (TCRT) EBIAT (2016 - 2025)
Alaunos Therapeutics (TCRT) has disclosed EBIAT for 15 consecutive years, with -$1.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 2.84% year-over-year to -$1.2 million, compared with a TTM value of -$4.0 million through Sep 2025, up 65.83%, and an annual FY2024 reading of -$4.7 million, up 86.68% over the prior year.
- EBIAT was -$1.2 million for Q3 2025 at Alaunos Therapeutics, down from -$1.1 million in the prior quarter.
- Across five years, EBIAT topped out at -$742000.0 in Q4 2024 and bottomed at -$22.7 million in Q3 2021.
- Average EBIAT over 5 years is -$8.4 million, with a median of -$8.8 million recorded in 2023.
- The sharpest move saw EBIAT decreased 21.91% in 2021, then surged 90.54% in 2024.
- Year by year, EBIAT stood at -$11.8 million in 2021, then grew by 22.34% to -$9.2 million in 2022, then grew by 14.37% to -$7.8 million in 2023, then soared by 90.54% to -$742000.0 in 2024, then tumbled by 56.2% to -$1.2 million in 2025.
- Business Quant data shows EBIAT for TCRT at -$1.2 million in Q3 2025, -$1.1 million in Q2 2025, and -$1.1 million in Q1 2025.